Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Olalekan O OluwoleRongzhe LiuIbrahim DiakiteChaoling FengAnik PatelIman NourhusseinJulia Thornton SniderFrederick L LockePublished in: Journal of medical economics (2022)
In the US, axi-cel is a potentially cost-effective treatment option compared with liso-cel for adult patients with r/r LBCL after two or more systemic therapy lines.